MedTrace Logo

Gazyva Infusion Reaction Investigation

NCT03529227 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2022-02-14

No results posted yet for this study

Summary

The study evaluate safety and effectiveness of chlorambucil and obinutuzumab in routine clinical practice in patients with chronic lymphatic leukemia and with certain comorbidities (any cardiac pathology, diabetes mellitus (DM), kidney pathology or cytopenia), whom obinutuzumab \& chlorambucil have been applied according to indications before enrollment in the study.

Conditions

Sponsors & Collaborators

  • Healthy Future

    lead OTHER

Principal Investigators

  • Eugeny A Nikitin, MD · "The State Budgetary Moscow Healthcare Institution Clinical Hospital named after S.P. Botkin of Moscow Health Department"

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-31
Primary Completion
2024-08-31
Completion
2025-04-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03529227 on ClinicalTrials.gov